Struggling Unigene slashes staff in reorganization

With its lead product Fortical under critical review on both sides of the Atlantic, Boontin, NJ-based Unigene Laboratories ($UGNE) has opted to slash its workforce by 40% in a restructuring. Most of the jobs being cut involve staffers who have been working on Fortical. An FDA panel recommended recently that the drug should not be used, as there's no evidence that calcitonin salmon works to strengthen bones and may increase the risk of cancer. The biotech company also said that it has lined up a $750,000 loan for additional working capital. Release


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.